Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. develops precision oncology medicines using its proprietary Generative Phosphoproteomics AP3 platform for drug design and predictive clinical development. The company’s recurring news centers on ACR-368, also known as prexasertib, a CHK1/2 inhibitor being developed with the ACR-368 OncoSignature assay for endometrial cancer, as well as ACR-2316, a WEE1/PKMYT1 inhibitor, and ACR-6840, a CDK11 development candidate.
Company updates commonly cover clinical and preclinical oncology data, scientific meeting presentations, FDA Fast Track and Breakthrough Device designations tied to ACR-368 and its assay, financial results, equity award disclosures, and the company’s internal CLIA-certified laboratory for patient testing and companion diagnostic development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will participate in a fireside chat on May 2, 2023, at 3:00 p.m. ET during the H.C. Wainwright BioConnect Investor Conference in New York. The company focuses on developing precision oncology medicines using its proprietary proteomics-based platform, known as Acrivon Predictive Precision Proteomics (AP3). Acrivon’s leading candidate, ACR-368, targets CHK1 and CHK2 and is in a Phase 2 trial for various tumor types. The OncoSignature® companion diagnostics, although not yet regulatory approved, aim to identify patients likely to benefit from ACR-368. Acrivon also explores preclinical programs targeting other nodes in DNA Damage Response, including WEE1 and PKMYT1.
Acrivon Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ACRV), will host a virtual investor event on May 1, 2023, from 11:00 a.m. to 12:00 p.m. ET. The agenda includes a company overview, an update on the Acrivon Predictive Precision Proteomics (AP3) platform, details on the preclinical pipeline, clinical trial enrollment progress, and corporate updates.
The event can be accessed via the company’s investor website, and a replay will be available for 90 days. Acrivon focuses on precision oncology medicines, utilizing its AP3 platform for patient responder identification and developing the lead candidate ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial across various tumor types. The company is also exploring additional preclinical programs targeting critical nodes in DNA Damage Response.
Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that its CEO, Peter Blume-Jensen, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days Conference on April 25, 2023, at 3:00 p.m. ET. This event will be held virtually and will focus on Acrivon’s advancements in precision oncology medicines.
Acrivon’s proprietary platform, AP3, matches patients’ tumor sensitivities to specific drugs. The company is advancing its lead candidate, ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial. Acrivon also develops OncoSignature companion diagnostics to identify patients most likely to benefit from its drug candidates. A replay of the webcast will be available for 90 days after the event.